MAAT INDEX

CLAIM #58945 · UnitedHealth Group Incorporated (UNH) · 2025Q4 earnings call · Jan 27, 2026 · due Dec 31, 2026

Growth rates will remain somewhat tempered in 2026, but strategic refocus and investment in modern next generation services should lead to growing momentum in the back half of the year that will carry into 2027 and beyond.

Patrick Conway · CEO, Optum

PENDING
graded after results covering Dec 31, 2026 are reported

How to check this claim

Look at: Optum segment adjusted operating earnings growth, quarter over quarter year-over-year comparison across 2026

It came true if: Year-over-year adjusted operating earnings growth rate in H2 2026 (Q3+Q4) higher than growth rate in H1 2026 (Q1+Q2)

Where: UnitedHealth Group quarterly earnings releases and segment reporting (10-Q/10-K, Optum segment results)

In context

'll turn it over to Patrick Conway CEO of Optum. Patrick Conway: Thanks, Tim. And good morning, everyone. As we start 2026, Optum will be anchored around relentless focus on improved and consistent execution. In OptumHealth and OptumInsight. That will enable future margin expansion and top line growth. OptumRx will remain focused on maintaining its market position and providing a more comprehensive suite of pharmacy benefits and services. And continuing to pursue success in winning new customers for 2027 and 2028. All in highly competitive markets. Our 2026 performance outlook reflects adjusted earnings growth in all three segments of our business, ranging from low to high single digit year over year performance and margin expansion ranging from 20 to 90 basis points across the portfolio. Growth rates will remain somewhat tempered in 2026, but strategic refocus and investment in modern next generation services should lead to growing momentum in the back half of the year that will carry into 2027 and beyond. Some details on each of our segments, starting with OptumRx. At OptumRx, we expect operating earnings growth from expanding margins by 20 basis points. On an adjusted basis. This growth is driven by a strong external selling season, that will impact 2026 and 2027 as we implement and expand over 800 new customer relationships. While new customer wins were offset by membership contraction at UnitedHealthcare, we are capitalizing on significant AI automation enabled operating to support our expanded margin outlook. In 2026. Entering 2026, we have implemented new pricing models that will deliver greater transparency to customers and cost based reimbursement. To pharmacies. We have removed reauthorization requirements for 180 drugs benefiting millions of people and we will continue to expand t

Verify independently

SEC filings for UNH · Claim quote is verbatim from the 2025Q4 earnings call.